News | Oncology Diagnostics | August 24, 2018

European team develops magnetoferritin compound to improve the quality of MRI imaging for oncology diagnostics

Scientists Develop New MRI Tool for Cancer Diagnosis and Therapy

Researchers in the laboratory ‘Biomedical Nanomaterials’ of NUST MISIS. Image courtesy of PR Newsfoto/NUST MISIS.


August 24, 2018 — A European research group has developed a system that allows doctors to both improve the accuracy of diagnosing malignant cells and to provide additional opportunities for cancer treatment. The magnetoferritin compound is the main element of the new system. The research article has been published in Advanced Functional Materials.

The research team consists of scientists from the National University of Science and Technology (NUST) MISIS (Moscow), the Technical University of Munich, Helmholtz Zentrum München, the University of Duisburg-Essen, and the University of Oldenburg.

The lack of accuracy (contrast) in imaging is a common problem of non-invasive diagnosis. Contrast agents, compounds that are introduced into the body before a diagnostic procedure to enhance the response and make affected cells more visible on a tomograph, can be used to solve this problem in magnetic resonance imaging (MRI). Paramagnetic gadolinium particles and superparamagnetic iron particles are among these agents. However, even in small quantities, these substances — alien to the human body — can potentially be dangerous.

"The international research team, including Dr. Ulf Wiedwald, a visiting professor at the NUST MISIS Biomedical Nanomaterials Laboratory, has developed a unique injection diagnosis system based on magnetoferritin. The developed system will significantly improve the quality of MRIs and optical diagnosis," said Alevtina Chernikova, rector of NUST MISIS.

Magnetoferritin is a compound consisting of endogenous human protein (ferritin) and a magnetic nucleus. The development and testing of the compound was conducted following the existing protocol for the synthesis of magnetoferritin, but was improved for the effective capture of tumor cells. The high concentration of magnetoferritin in tumor tissue made it possible to obtain a hypoallergenic contrast agent that is perfectly compatible with the human body.

"An intravenous injection of magnetoferritin has been proposed. Then, spreading with the blood flow, [the magnetoferritin] will be captured by the targeted tumor cells. As has been shown in a large number of studies, these cells actively capture transferrin - the protein responsible for the transport of iron in the blood. The same receptors are capable of capturing the magnetoferritin as well. Once they get into the lysosomes of targeted cells, the magnetoferritin will further enhance the contrast signal," commented Wiedwald.

The system will also allow doctors to conduct therapy on tumor formations. If an MRI shows cancerous cells, they can be targeted by an electromagnetic field or light, which will lead to their heating and subsequent death.

For more information: www.onlinelibrary.wiley.com

Reference

Massner C., Sigmund F., Pettinger S., et al. Genetically Controlled Lysosomal Entrapment of Superparamagnetic Ferritin for Multimodal and Multiscale Imaging and Actuation with Low Tissue Attenuation. Advanced Functional Materials, March 13, 2018. https://doi.org/10.1002/adfm.201706793


Related Content

News | Cardiac Imaging

February 12, 2024 — According to the American Journal of Roentgenology (AJR), free-breathing cine-deep learning (DL) may ...

Time February 12, 2024
arrow
News | FDA

February 12, 2024 — Proscia, a leading provider of digital and computational pathology solutions, has received 510(k) ...

Time February 12, 2024
arrow
News | SNMMI

February 6, 2024 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) held its 2024 SNMMI Mid-Winter Meeting ...

Time February 06, 2024
arrow
News | Radiology Business

January 25, 2024 — Esaote Group, a leading Italian innovator in medical imaging, today unveiled its new brand identity ...

Time January 25, 2024
arrow
News | Artificial Intelligence

January 23, 2024 — Quibim announced it has added an industry-leading cancer detection capability to its prostate tool ...

Time January 22, 2024
arrow
Feature | Contrast Media Injectors | By Christine Book

Contrast media injectors are used to inject contrast media or contrast agents to enhance the blood and perfusion in ...

Time January 17, 2024
arrow
News | Artificial Intelligence

December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based ...

Time December 22, 2023
arrow
News | Magnetic Resonance Imaging (MRI)

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for ...

Time December 20, 2023
arrow
News | Radiology Business

December 13, 2023 — The global medical technology company 4DMedical has announced it has entered a binding agreement to ...

Time December 13, 2023
arrow
News | Contrast Media

December 11, 2023 — Bracco Imaging S.p.A., an innovative world leader delivering end-to-end products and solutions ...

Time December 11, 2023
arrow
Subscribe Now